Imidazolinone ring system is of biological and chemical interest since long. The imidazolinones\[[@CIT1]\] are associated with a wide range of therapeutic activities\[[@CIT2]--[@CIT7]\] such as anticonvulsant, sedative and hypnotic, potent CNS depressant, antihistamine, antifilarial, bactericidal, fungicidal, antiinflammatory, MAO inhibitory, antiparkinsonian, antihypertensive and anthelmintic. Recently some new imidazolinone derivatives have been reported as antiinflammatory, herbicidal and hypertensive activities. Some workers have recognized 5-imidazolone as having anticancer activity\[[@CIT8]\]. The therapeutic importance of the compounds inspired us to synthesize some potential imidazolinones\[[@CIT9]--[@CIT13]\].

Desai *et al.*\[[@CIT14]\] have synthesized 4-benzylidene-2-phenyloxazole-5-one based on the methods descried in the literature which is a special type of Perkin condensation in which reaction between aldehyde and benzoylglycine proceeds first followed by ring closer. It is observed that aldehyde condenses under the influence of a base with the reactive methylene group in the azalactone which is formed by the dehydration of benzoylglycine, when the latter reacts with Ac~2~ O in presence of sodium acetate. In view of these observations, we have synthesized imidazol-5-ones ([Scheme I](#F0001){ref-type="fig"}, [Table 1](#T0001){ref-type="table"}).

![Synthetic pathway for synthesis of 5-imidazolone derivatives](IJPhS-71-90-g001){#F0001}

###### 

PHYSICAL CONSTANTS AND ELEMENTAL ANALYSIS OF 5-IMIDAZOLNES4a-q, 5a-o AND 6a-m

  Sr No   Ar-                            Molecular Formula           M.P.   Yield (%)   Elemental Analysis                   
  ------- ------------------------------ --------------------------- ------ ----------- -------------------- ------- ------- -------
  4a      C~6~H~5~                       C~22~H~13~Cl~3~N~2~O        173    65          61.78                61.69   6.55    6.41
  4b      2-OH-C~6~H~4~                  C~22~H~13~Cl~3~N~2~O~2~     170    60          59.55                59.47   6.31    6.25
  4c      4-OCH~3~-C~6~H~4~              C~23~H~15~Cl~3~N~2~O~2~     160    55          60.35                60.28   6.12    6.03
  4d      3-Cl-C~6~H~4~                  C~22~H~12~Cl~4~N~2~O        185    54          57.17                57.06   6.06    6.01
  4e      3-OCH~3~-C~6~H~4~              C~23~H~15~Cl~3~N~2~O~2~     190    50          60.35                60.21   6.12    6.03
  4f      2-Cl-C~6~H~4~                  C~22~H~12~Cl~4~N~2~O        195    53          57.17                57.06   6.06    5.98
  4g      4-Cl-C~6~H~4~                  C~22~H~12~Cl~4~N~2~O        210    54          57.17                57.05   6.06    6.01
  4h      2-NO~2~-C~6~H~4~               C~22~H~12~Cl~3~N~3~O~3~     180    57          55.90                55.79   8.89    8.80
  4i      3-NO~2~-C~6~H~4~               C~22~H~12~Cl~3~N~3~O~3~     230    55          55.90                55.74   8.89    8.78
  4j      3-OCH~3~-4-OH-C~6~H~3~         C~23~H~15~Cl~3~N~2~O~3~     170    65          58.31                58.21   5.91    5.70
  4k      5-Br-3OCH~3~-4-OH-C~6~H~2~     C~23~H~14~BrCl~3~N~2~O~3~   235    68          49.99                49.85   5.07    4.98
  4l      4-OH-C~6~H~4~                  C~22~H~13~Cl~3~N~2~O~2~     145    57          59.55                59.36   6.31    6.21
  4m      5-Br-2OH-C~6~H~3~              C~22~H~12~BrCl~3~N~2~O~2~   175    50          50.56                50.45   5.36    5.22
  4n      3-OC~6~H~5~-C~6~H~4~           C~28~H~17~Cl~3~N~2~O~2~     160    48          64.70                64.64   5.39    5.34
  4o      2,4,5 (OCH~3~)3-C~6~H~2~       C~25~H~19~Cl~3~N~2~O~4~     198    45          57.99                57.90   5.41    5.33
  4p      3,4,5 (OCH~3~)3-C~6~H~2~       C~25~H~19~Cl~3~N~2~O~4~     185    45          57.99                57.89   5.41    5.35
  4q      3-OH-C~6~H~4~                  C~22~H~13~Cl~3~N~2~O~2~     165    58          59.55                57.47   6.31    6.26
  5a      C~6~H~5~                       C~23~H~16~ClN~3~O~2~        233    60          68.74                68.62   10.46   10.35
  5b      2-OH-C~6~H~4~                  C~23~H~16~ClN~3~O~3~        235    65          66.11                66.05   10.06   9.97
  5c      3-Cl-C~6~H~4~                  C~23~H~15~Cl~2~N~3~O~2~     237    66          63.32                63.20   9.63    9.51
  5d      3-OCH~3~-C~6~H~4~              C~24~H~18~ClN~3~O~3~        246    55          66.75                66.66   9.37    9.29
  5e      2-Cl-C~6~H~4~                  C~23~H~15~Cl~2~N~3~O~2~     212    62          63.32                63.19   9.63    9.51
  5f      4-Cl-C~6~H~4~                  C~23~H~15~Cl~2~N~3~O~2~     214    64          63.32                63.23   9.63    9.54
  5g      2-NO~2~-C~6~H~4~               C~23~H~15~ClN~4~O~4~        248    50          61.82                61.73   12.54   12.45
  5h      3-NO~2~-C~6~H~4~               C~23~H~15~ClN~4~O~4~        223    56          61.82                61.69   12.54   12.47
  5i      3-OCH~3~-4-OH-C~6~H~3~         C~24~H~18~ClN~3~O~4~        226    45          64.36                64.25   9.38    9.25
  5j      4-OH-C~6~H~4~                  C~23~H~16~ClN~3~O~3~        231    47          66.11                66.01   10.06   9.98
  5k      3-OC~6~H~5~-C~6~H~4~           C~29~H~20~ClN~3~O~3~        186    48          70.52                70.40   8.51    8.39
  5l      2,4,5 (OCH~3~)3-C~6~H~2~       C~26~H~22~ClN~3~O~5~        245    46          63.48                63.40   8.54    8.47
  5m      3,4,5 (OCH~3~)3-C~6~H~2~       C~26~H~22~ClN~3~O~5~        210    50          63.48                63.41   8.54    8.45
  5n      3-OH-C~6~H~4~                  C~23~H~16~ClN~3~O~3~        182    57          66.11                66.02   10.06   9.98
  5o      4-N(C~2~H~5~)2-2-OH-C~6~H~3~   C~27~H~25~ClN~4~O~3~        176    43          66.21                66.21   11.46   11.40
  6a      2-OH-C~6~H~4~                  C~23~H~15~Cl~2~N~3~O~3~     175    60          61.08                61.01   9.29    9.93
  6b      3-Cl-C~6~H~4~                  C~23~H~14~Cl~3~N~3~O~2~     208    58          58.68                58.61   8.39    8.88
  6c      3-OCH~3~-C~6~H~4~              C~24~H~17~Cl~2~N~3~O~3~     202    55          61.82                61.70   9.01    5.90
  6d      2-Cl-C~6~H~4~                  C~23~H~14~Cl~3~N~3~O~2~     205    56          58.68                58.58   8.93    8.85
  6e      4-Cl-C~6~H~4~                  C~23~H~14~Cl~3~N~3~O~2~     244    55          58.68                58.59   8.93    8.87
  6f      2-NO~2~-C~6~H~4~               C~23~H~14~Cl~2~N~4~O~4~     216    58          57.40                57.31   11.64   11.55
  6g      3-NO~2~-C~6~H~4~               C~23~H~14~Cl~2~N~4~O~4~     233    60          57.40                57.32   11.64   11.56
  6h      3-OCH~3~-4-OH-C~6~H~3~         C~24~H~17~Cl~2~N~3~O~4~     237    48          59.77                59.65   8.74    8.65
  6i      4-OH-C~6~H~4~                  C~23~H~15~Cl~2~N~3~O~3~     236    45          61.08                61.01   9.29    9.22
  6j      3-OC~6~H~5~-C~6~H~4~           C~29~H~19~Cl~2~N~3~O~3~     224    48          65.92                65.80   7.95    7.81
  6k      2,4,5 (OCH~3~)3-C~6~H~2~       C~26~H~21~Cl~2~N~3~O~5~     238    43          59.33                59.27   7.98    7.90
  6l      3,4,5 (OCH~3~)3-C~6~H~2~       C~26~H~21~Cl~2~N~3~O~5~     212    45          59.33                59.26   7.98    7.88
  6m      3-OH-C~6~H~4~                  C~23~H~14~Cl~2~N~3~O~3~     190    48          61.08                61.01   9.29    9.20

Various 4-arylidene-2-phenyl-1-(2,4,5-trichlorophenyl)-1*H*-imidazol-5(4*H*)-ones (4a-q) were prepared by the reaction of 2,4,5-trichlorobenzenamine with 4-arylidene-2-phenyloxazol-5(4*H*)-ones (3a-q). *N*-(4-benzylidene-5-oxo-2-phenyl-4,5-dihydroimidazol-1-yl)-4-chlorobenzamide (5a-o) were synthesized by the reaction of 4-chlorobenzohydrazide and 4-arylidene-2-phenyloxazol-5(4*H*)-ones (3a-q). *N*-(4-benzylidene-5-oxo-2-phenyl-4,5-dihydroimidazol-1-yl)-2,4-dichlorobenzamides (6a-m) were obtained by the reaction of 2,4-dichlorobenzohydrazide with 4-arylidene-2-phenyloxazol-5(4*H*)-ones (3a-q).

Melting points were taken in open capillaries using paraffin bath and are uncorrected. IR spectra were recorded on FTIR-Perkin-Elmer spectrometer (V~max~ cm^−1^); ^1^H NMR spectra were recorded on Bruker Avance 300 FT-NMR spectrometer using CDCl~3~ as a solvent and mass spectra carried out on JEOL SX 102/DA-600 mass spectrometer, respectively. All the compounds were analyzed for carbon, hydrogen and nitrogen and the results were within ±0.4% of theoretical values. Purity was checked by TLC using TLC aluminum sheets silica gel 60, supplied by E. Merck, Mumbai, India. The spots were located by keeping the plates in iodine vapor and 2,4,5-trichlorobenzenamine was supplied by S. D. Fine Chem Limited, Mumbai, India. 4-Chlorobenzohydrazide, 2,4-dichlorobenzo hydrazide and 4-arylidene-2-phenyloxazol-5(4*H*)-one (3a-q), were prepared as given in literature method\[[@CIT15]--[@CIT20]\].

4-Arylidene-2-phenyl-1-(2,4,5-trichlorophenyl)-1*H*-imidazol-5(4*H*)-one (4) were synthesized as follows; A mixture of 2,4,5-trichloroaniline (0.01 mol) and 4-(arylidene)-2-phenyloxazol-5(4*H*)-ones (0.01 mol) was placed in a round bottom flask and 10 ml of pyridine were added to it. The reaction mixture was refluxed on a sand bath for 6 h. ([scheme I](#F0001){ref-type="fig"}) and the mixture was poured into ice-cold water and then a required amount of conc. hydrochloric acid was added to neutralize the reaction mixture. The progress of the reaction and the purity of compounds were routinely checked on TLC. The solid obtained was left overnight, filtered and washed with water. The product was dried and recrystallized from ethanol (99%). m.p.195° Yield 53% anal. found: C, 57.06; N, 5.98; calc for C~22~ H~12~ Cl~4~ N~2~ O: C, 57.17; N, 6.06%.

Compound 4f: IR (KBr): 3062 cm^−1^ (-C-H str., aromatic), 1643 cm^−1^ (\>C=O str., cyclic ring), 1359 cm^−1^ (\>C=N str., imidazol ring), 1284 cm^−1^ (-C-N tertiary amine), 1074 cm^−1^ (-C-Cl str., aromatic), 744 cm^−1^ (\>C=CH medium), 704, 688, 613 cm^−1^ (trisubstituted aromatic). ^1^H NMR (CDCl~3~): δ7.2 (s, 1H, -CH), 7.26-8.54 (m, 11H, Ar-H, C=C-Ar) ppm. MS: m/z 461 with 62% relative intensity (base peak) & 462 with 47% relative intensity (M^+^). Other compounds of the series were prepared by using a similar method and their physical data are recorded in [Table 1](#T0001){ref-type="table"}.

*N*-(4-benzylidene-5-oxo-2-phenyl-4,5-dihydroimidazol-1-yl)-4-chlorobenzamides (5)/ *N*-(4-benzylidene-5-oxo-2-phenyl-4,5-dihydroimidazol-1-yl)-2,4-dichlorobenzamides (6) were prepared using the following procedure; A mixture of 4-chlorobenzohydrazide/ 2,4-dichlorobenzohydrazide (0.01 mol) and 4-(arylidene)-2-phenyloxazol-5(4*H*)-ones (0.01 mol) was placed in a round bottom flask and 10 ml of pyridine was added to this mixture. The reaction mixture was refluxed on a sand bath for 6 h ([Scheme I](#F0001){ref-type="fig"}). The mixture was poured into ice-cold water and then required amount of con. hydrochloric acid was added to neutralize the reaction mixture. The solid obtained was left overnight, filtered and washed with water. The product was dried and recrystallized from ethanol (99%).

Compound 5f: IR (KBr): 3249 cm^−1^ (medium --CONH-), 3033 cm^−1^ (-C-H str., aromatic), 1656 cm^−1^ (\>C=O str., cyclic ring), 1625 cm^−1^ (\>C=N str., imidazol ring), 1490 cm^−1^ (\>NH weak), 1299 cm^−1^ (-C-N tertiary amine), 1095 cm^−1^ (-C-Cl str., aromatic), 754 cm^−1^ (\>C=CH medium), 707 cm^−1^ (monosubstituted aromatic). ^1^H NMR (CDCl~3~): δ7.28 (s, 1H, -CH), 7.26-8.54 (m, 13H, Ar-H, -C=C-Ar), 10.02 (s, 1H, -NH-CO-) ppm. MS: m/z 436 with 45% relative intensity (base peak) & 437 with 32% relative intensity (M^+^).

Compound 6e: IR (KBr): 3213 cm^−1^ (medium, --CONH-), 2993 cm^−1^ (-C-H str., aromatic), 1662 cm^−1^ (\>C=O str., cyclic ring), 1635 cm^−1^ (\>C=N str., imidazol ring), 1473 cm^−1^ (\>NH weak), 1305 cm^−1^ (-C-N tertiary amine), 1109 cm^−1^ (-C-Cl str., aromatic), 925 cm^−1^ (\>C=CH medium), 825, 713 cm^−1^ (disubstituted aromatic), 707 cm^−1^ (monosubstituted aromatic). ^1^H NMR (CDCl~3~): δ7.2 (s, 1H,-CH), 7.32-8.05 (m, 12H, Ar-H, C=C-Ar), 10.02 (s,1H, -NH-CO-) ppm. MS: m/z 471 with 79% relative intensity (base peak) and 472 with 51% relative intensity (M^+^). Other compounds of the series were prepared by using a similar method and their physical data are recorded in [Table 1](#T0001){ref-type="table"}.

Antibacterial activity was carried out by broth dilution method\[[@CIT21]\]. The strains used for the activity were procured from Institute of Microbial Technology, Chandigarh. The compounds 4a-q, 5a-o and 6a-m were screened for their antibacterial activity against *Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa* and *Staphylococcous pyogenes* at concentrations of 1000, 500, 200, 100, 50, 25, 12.5 µg/ml respectively ([Table 2](#T0002){ref-type="table"}). Same compounds were tested for antifungal activity against *C. albicans, A. niger* and *A. clavatus* at concentrations of 1000, 500, 200, and 100 µg/ml respectively ([Table 2](#T0002){ref-type="table"}). The results are recorded in the form of primary and secondary screening.

###### 

ANTIBACTERIAL AND ANTIFUNGAL ACTIVITIES OF THE SYNTHESIZED COMPOUNDS[\*](#TF0002){ref-type="table-fn"}

  Sr. No.   Minimal bactericidal concentration (MBC) in μg/ml   Minimal fungicidal concentration (MFC) in μg/ml                         
  --------- --------------------------------------------------- ------------------------------------------------- ---- ---- ----- ----- -----
  4a        25                                                  \-                                                \-   \-   \-    \-    \-
  4b        25                                                  50                                                \-   \-   \-    \-    \-
  4f        100                                                 \-                                                \-   \-   100   100   100
  4i        25                                                  \-                                                \-   \-   \-    \-    \-
  4j        25                                                  \-                                                \-   \-   \-    \-    \-
  4k        50                                                  100                                               50   \-   \-    \-    \-
  4q        50                                                  100                                               \-   \-   \-    \-    \-
  5b        \-                                                  \-                                                \-   \-   100   100   100
  5e        50                                                  50                                                \-   \-   \-    \-    \-
  6f        100                                                 \-                                                \-   \-   100   100   100
  6j        \-                                                  \-                                                \-   \-   \-    \-    100
  6l        \-                                                  \-                                                \-   \-   100   \-    100
  6m        \-                                                  \-                                                \-   \-   100   \-    \-

Gentamycin is used as standard for antibacterial activity which showed (0.05, 0.25, 0.5 and 1 μg/ml) MBC against *E. coli*, *S. aureus*, *S. pyogenus* and *P. aeruginosa* respectively. K nystatin was used as the standard for antifungal activity which showed 100 μg/ml MFC against fungi, used for the antifungal activity.

All the compounds were tested for the antibacterial and antifungal activities but data of active compounds have been reported as present protocol

The synthesized compounds found to be active in the primary screening were further tested in a second set of dilution against all microorganisms. The compounds found active in primary screening were similarly diluted to obtain 100, 50, 25 μg/ml concentrations. Ten microlitres suspensions from each well were further inoculated on appropriate media and growth was noted after 24 and 48 h. The lowest concentration, which showed no growth after spot subculture was considered as MBC/MFC for each drug. The highest dilution showing at least 99% inhibition was taken as MBC/MFC. The result of this test is affected by the size of the inoculums. The test mixture should contain 10^8^ organisms/ml. For antibacterial activity, in present protocol 50 µg/ml is considered as active as compared to the standard drug gentamycin. For antifungal activity, 100 µg/ml is considered as active as compared to standard nystatin. Compounds 4a, 4b, 4i, 4j, 4k, 4q and 5e are active on *E. coli* where as 4b and 5e are active on *P. aeruginosa*. Compound 4k is active on *S. aureus* and 6m is also active on *S. pyogens.* Compounds 4f, 5b, 6f, 6l, and 6m are active on fungi strains. On the basis of biological activity results, it may be concluded that the introduction of OH, OCH~3~, NO~2~, Cl and Br groups to the heterocyclic frame work enhanced antibacterial and antifungal activities.
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